SUBSCRIBERS

Novartis puts pressure on Roche with cheap copy of Rituxan

Published Mon, Jun 19, 2017 · 09:50 PM

Zurich

SWITZERLAND'S Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.

Rixathon, from Novartis's Sandoz generics unit, follows Celltrion's Truxima that secured the European Commission's blessing in February to be used against diseases including non-Hodgkin's lymphoma and …

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

Companies & Markets

Novartis puts pressure on Roche with cheap copy of Rituxan

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece

P&G raises annual core profit forecast on resilient demand, price hikes

Cordlife calls for trading halt after shares sink to all-time low, pending announcement

Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom

Swiss watch exports plunge as China and Hong Kong demand dries up

Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT